JAK1 and infection: This approach, further validated by functional assay, both in vitro and ex vivo, allowed the identification of novel JAK1 GOF variants in five patients presenting with broad clinical manifestations, including autoimmune hepatitis and recurrent infections, and defined targeted therapeutic strategies.